Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: klm981 who wrote (1120)	3/6/2000 7:58:00 AM
From: swisstrader	Read Replies (2) \| Respond to of 1605

Just posted for the sake of argument and if you are keep current on VASO, they have started to evaluate alternative pricing strategies and one such strategy would include royalty based pricing arrangements...the only thing stopping them is existing contracts with some 140 centers and the fact that they already enjoy a 70% markup on the EECP machines...and p.s. I do know the company quite well, which is perhaps why I've enjoyed this recent run since 2.00, and while HOW they generate revenue is tantamount to VASO's success, at this stage of the game, THE PROCEDURE and the success rates are much more important than precisely how their revenue stream will be derived...now I gotta run, VASO CEO on Bloomberg!